Critical care medicine
-
Critical care medicine · Sep 2022
Randomized Controlled Trial Multicenter StudyA Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab for the Treatment of COVID-19 Pneumonia With Hyperinflammation.
We designed this study to test whether clazakizumab, a direct interleukin-6 inhibitor, benefits patients hospitalized with severe or critical COVID-19 disease accompanied by hyperinflammation. ⋯ Clazakizumab significantly improved 28-day ventilator-free survival, 28- and 60-day overall survival, as well as clinical outcomes in hospitalized patients with COVID-19 and hyperinflammation.
-
Critical care medicine · Sep 2022
Randomized Controlled TrialDaily Written Care Summaries for Families of Critically Ill Patients: A Randomized Controlled Trial.
To determine the effect of daily written updates on the satisfaction and psychologic symptoms of families of ICU patients. ⋯ Written communication improved satisfaction and the emotional well-being of families of critically ill patients, supporting its use as a supplement to traditional communication approaches.
-
Critical care medicine · Sep 2022
Comment Letter Randomized Controlled TrialProof of Concept, Feasibility, and Efficacy Trials.